In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Arcus Biosciences trades 37.9% above its PERT-weighted fair value of $14.20, suggesting overvaluation risk relative to conservative DCF results and weighted valuation methods. Strong liquidity and growth coexist with zero profitability and efficiency, creating valuation divergence. Monte Carlo analysis shows negligible downside risk below the current price.